Amiodarone Use in Atrial Fibrillation: Indications, Efficacy, and Safety
1. Indications and Preferred Patient Populations
- Amiodarone is recommended as a second‑line agent for maintaining sinus rhythm in patients with structural heart disease (e.g., heart failure, left‑ventricular dysfunction, coronary artery disease) and in highly symptomatic patients without structural disease, because of its superior efficacy compared with other antiarrhythmics but a significant toxicity profile. 1
- The drug is specifically advised for rhythm maintenance after cardioversion and is not a first‑line option except in heart‑failure patients, per American Heart Association (AHA) guidance. [1][2]
- In patients with heart failure, amiodarone is the antiarrhythmic of choice because class IC agents are contraindicated. 2
2. Efficacy in Rhythm Control
2.1 Maintenance of Sinus Rhythm
| Study (Population) | Outcome | Effect |
|---|---|---|
| SAFE‑T trial (AF after cardioversion) | Median time to AF recurrence | 487 days with amiodarone vs 74 days with sotalol and 6 days with placebo [3][4] |
| Meta‑analysis of AF trials | AF recurrence prevention | 69 % with amiodarone vs 39 % with propafenone or sotalol (NNT = 3.6) [1] |
| Long‑term follow‑up (≈16 mo) | Maintenance of sinus rhythm | 65 % with amiodarone vs 37 % with sotalol/propafenone [5] |
| Heart‑failure cohort | Annual mortality | Reduced from 24.3 % to 19.9 % (ARR = 4.4 %, NNT = 23) [5] |
| Post‑cardioversion (6 mo) | Sinus‑rhythm persistence | 83 % with amiodarone vs 43 % with quinidine [6][7] |
| Refractory AF after failure of ≥2 class I agents (5‑yr) | Recurrence rate | 9 % recurrence with amiodarone [3][4] |
2.2 Acute Cardioversion
- Intravenous amiodarone does not outperform placebo at 1–2 h but becomes effective at 6–8 h and remains effective at 24 h, making it inferior to class IC agents for rapid conversion. 2
3. Safety, Monitoring, and Discontinuation
- Extracardiac toxicity is the principal limitation; 18 % of patients discontinue amiodarone because of side effects versus 11 % with sotalol/propafenone (European Society of Cardiology, ESC data). [8][7]
- Major adverse effects include pulmonary fibrosis, thyroid dysfunction, hepatitis, and neurotoxicity (guideline‑level warning).
- Monitoring: liver‑function tests and thyroid‑function tests should be performed at least every 6 months. 9
4. Regulatory Status and Guideline Position
- Amiodarone is not FDA‑approved for atrial fibrillation; its only approved indication is for life‑threatening ventricular arrhythmias. Nonetheless, ACC/AHA/ESC guidelines endorse its off‑label use for AF based on extensive clinical evidence. [5][1]
5. Practical Dosing
| Route | Loading Phase | Maintenance Phase |
|---|---|---|
| Oral | 600–800 mg daily until a cumulative 10 g is reached | 200 mg daily (or ≤200 mg to reduce toxicity) [1][8][7] |
| Intravenous | 150 mg bolus over 10 min, then 1 mg/min for 6 h, followed by 0.5 mg/min infusion | – [5] |
- Lower maintenance doses (≤200 mg daily) are associated with reduced toxicity while preserving efficacy. [8][7]
6. Drug‑Interaction Considerations
- Warfarin: Amiodarone prolongs prothrombin time; the effect peaks ≈7 weeks after initiation, requiring dose adjustment of warfarin. 9
- Digoxin: Levels may rise; close therapeutic‑drug monitoring and dose modification are necessary. 9
All facts are derived from cited peer‑reviewed sources and reflect guideline‑level recommendations where societies are identified.